Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
322 studies found for:    "Vasculitis"
Show Display Options
Rank Status Study
1 Active, not recruiting Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
Condition: Vasculitis
Intervention: Drug: azathioprine
2 Recruiting Endothelin Antagonism in ANCA Vasculitis
Condition: Vasculitis
Intervention: Drug: BQ123 or BQ123/788
3 Completed Clinical Trial of Mycophenolate Versus Cyclophosphamide in ANCA Vasculitis
Condition: Vasculitis
Interventions: Drug: mycophenolate mofetil;   Drug: cyclophosphamide
4 Completed Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis
Condition: ANCA-associated Vasculitis
Interventions: Drug: CCX168 low dose plus standard of care;   Drug: CCX168 high dose plus standard of care;   Other: Placebo BID plus standard of care
5 Terminated Hematopoietic Stem Cell Support in Vasculitis
Condition: Vasculitis
Interventions: Biological: Autologous Stem Cell Transplant;   Biological: Allogeneic Stem Cell Transplant
6 Recruiting Optical Coherence Tomography (OCT) in Retinal Vasculitis
Condition: Retinal Vasculitis
Intervention:
7 Withdrawn Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens
Condition: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions: Drug: Retinoic acid;   Drug: Standard of care
8 Completed A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis
Condition: Vasculitis
Interventions: Drug: Placebo;   Drug: CCX168
9 Completed Biological Markers in Retinal Vasculitis
Condition: Retinal Vasculitis
Intervention:
10 Recruiting A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
Condition: ANCA-Associated Vasculitis
Interventions: Drug: CCX168;   Drug: Prednisone;   Drug: Cyclophosphamide;   Biological: Rituximab;   Drug: Azathioprine
11 Withdrawn Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab
Condition: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions: Drug: Standard of care treatment;   Drug: eculizumab
12 Recruiting IgA-positive Versus IgA-negative Immune Complex Vasculitis
Condition: Cutaneous Vasculitis
Intervention:
13 Terminated Abatacept in ANCA Associated Vasculitis
Condition: ANCA-associated Vasculitis
Intervention: Drug: Abatacept (Orencia)
14 Completed Magnetic Resonance Angiography vs Ultrasonography in Systemic Large vEssel vasculitiS
Condition: Systemic Vasculitis
Interventions: Device: Ultrasound;   Device: MRA
15 Terminated
Has Results
Defining Immune Tolerance in ANCA-associated Vasculitis (AAV)
Condition: ANCA-Associated Vasculitis
Intervention: Procedure: Venipuncture for blood sample collection
16 Recruiting MICRO-RNAs OF NEUTROPHILS IN RENAL ANTINEUTROPHIL CYTOPLASMIS ANTIBODY (ANCA) -ASSOCIATED VASCULITIS
Condition: ANCA-associated Vasculitis
Intervention: Other: Non interventional study
17 Completed Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients
Condition: Cryoglobulinemia Vasculitis
Intervention: Drug: Proleukin
18 Completed MMF Versus CTX in the Induction Treatment of ANCA Associated Vasculitis
Conditions: Vasculitis;   Anti-Neutrophil Cytoplasmic Antibody
Intervention: Drug: mycophenolate mofetil
19 Recruiting Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing
Condition: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Intervention: Drug: Rituximab
20 Completed Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses
Conditions: Urticaria;   Vasculitis
Intervention: Drug: canakinumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.